Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • macitentan

    - PMLiVE

    Merck’s Winrevair granted MHRA approval to treat pulmonary arterial hypertension

    The drug has been authorised for use in adults with moderate or marked limitations of physical activity

    - PMLiVE

    Merck shares positive phase 3 results for pulmonary arterial hypertension therapy

    The progressive blood vessel disorder affects approximately 40,000 people in the US

    - PMLiVE

    Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension

    Yuvanci is now the only single tablet combination therapy for PAH patients in Europe

    - PMLiVE

    Merck’s Winrevair receives EC approval to treat pulmonary arterial hypertension in adults

    About 30,000 people in the EU are living with the progressive blood vessel disorder

    - PMLiVE

    Johnson & Johnson’s Yuvanci recommended by CHMP to treat pulmonary arterial hypertension

    The rare form of pulmonary hypertension affects around 30,000 people in the EU

    - PMLiVE

    Merck’s pulmonary arterial hypertension therapy receives CHMP recommendation

    Approximately 30,000 people in the EU are currently living with the rare blood disorder

    - PMLiVE

    Janssen/Pharmacyclics’ ibrutinib shows continued survival benefit in chronic lymphocytic leukaemia

    The slow-growing blood cancer affects approximately 4.92 per 100,000 people every year in Europe

    - PMLiVE

    How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

    PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...

    Inizio

    - PMLiVE

    Merck’s Winrevair granted FDA approval to treat pulmonary arterial hypertension in adults

    The rare blood vessel disorder affects approximately 500 to 1,000 people in the US every year

    - PMLiVE

    Johnson & Johnson’s Opsynvi granted FDA approval in pulmonary arterial hypertension

    The rare form of pulmonary hypertension is responsible for up to 1,000 new cases in the US every year

    - PMLiVE

    Janssen’s Carvykti recommended by CHMP for earlier multiple myeloma treatment

    The blood cancer affects approximately 160,000 people worldwide

    - PMLiVE

    Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

    Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.

    Inizio

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links